Frazier Life Sciences Management L.P. Reduces Holdings in Tarsus Pharmaceuticals, Inc. $TARS

Frazier Life Sciences Management L.P. lessened its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 37.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 728,644 shares of the company’s stock after selling 438,883 shares during the period. Tarsus Pharmaceuticals accounts for 1.6% of Frazier Life Sciences Management L.P.’s investment portfolio, making the stock its 17th largest position. Frazier Life Sciences Management L.P.’s holdings in Tarsus Pharmaceuticals were worth $59,661,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Federated Hermes Inc. lifted its position in shares of Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after buying an additional 339 shares during the last quarter. Valeo Financial Advisors LLC lifted its position in shares of Tarsus Pharmaceuticals by 11.1% during the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock valued at $321,000 after buying an additional 392 shares during the last quarter. Creative Planning lifted its position in shares of Tarsus Pharmaceuticals by 3.3% during the 3rd quarter. Creative Planning now owns 12,367 shares of the company’s stock valued at $735,000 after buying an additional 393 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Tarsus Pharmaceuticals by 26.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company’s stock valued at $169,000 after buying an additional 431 shares during the last quarter. Finally, Comerica Bank lifted its position in shares of Tarsus Pharmaceuticals by 470.0% during the 4th quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after buying an additional 705 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TARS. Zacks Research cut Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Wall Street Zen raised Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. HC Wainwright reissued a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a report on Monday, May 4th. Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $90.67.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS opened at $61.95 on Friday. The stock’s 50-day simple moving average is $63.97 and its 200 day simple moving average is $70.01. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -54.34 and a beta of 0.49. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. The business had revenue of $162.05 million for the quarter, compared to analysts’ expectations of $149.60 million. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%. Research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -0.59 EPS for the current fiscal year.

Insider Activity

In other news, insider Jeffrey S. Farrow sold 2,186 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $146,462.00. Following the completion of the sale, the insider owned 43,316 shares in the company, valued at approximately $2,902,172. This trade represents a 4.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bobak R. Azamian sold 11,964 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $801,588.00. Following the sale, the chief executive officer owned 33,421 shares of the company’s stock, valued at approximately $2,239,207. This trade represents a 26.36% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 79,391 shares of company stock worth $5,432,035. Company insiders own 9.64% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.